Skip to main content
SpringerLink
Log in

Treatment of the Prostate Cancer

  • Chapter
Urological Cancer Management

  • 678 Accesses

Abstract

The treatment of prostate cancer is a very broad subject where many aspects have to be taken into consideration. Apart from urological surgeons, it involves many specialists from other fields such as medical and radiotherapeutic oncologists, pathologists, radiologists, anaesthetists, geriatricians and specialized nurses. Sometimes, the expertise of a psychologist is also required to assist patients and families receiving unfortunate news.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–80.

    Article  CAS  PubMed  Google Scholar 

  2. Staerman F, Peyromaure M, Irani J, Gaschignard N, Mottet N, Soulié M, et al. Place de la surveillance active dans le cancer de la prostate à faible risque de progression. Prog Urol. 2011;21:448–54.

    Article  CAS  PubMed  Google Scholar 

  3. Salomon L, Bastide C, Beuzeboc P, et al. Les membres du CCAFU. Recommandations en onco-urologie 2013 du CCAFU: Cancer de la prostate. Prog Urol 2013; 23(Suppl 2):S69–101.

    Google Scholar 

  4. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171(4):1520–4.

    Article  PubMed  Google Scholar 

  5. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009;55:1321–30.

    Article  PubMed  Google Scholar 

  6. Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol. 2011;35:1351–5.

    Article  PubMed  Google Scholar 

  7. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55(1):1–8.

    Article  PubMed  Google Scholar 

  8. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. The European Association of Urology. 2014.http://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf#

  9. Sun M, Sammon JD, Becker A, Roghmann F, Tian Z, Kim SP, Larouche A, Abdollah F, Hu JC, Karakiewicz PI, Trinh QD. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int. 2014;113(2):200–8.

    Article  PubMed  Google Scholar 

  10. Moran PS, O’Neill M, Teljeur C, Flattery M, Murphy LA, Smyth G, et al. Robot- assisted radical prostatectomy compared with open and laparoscopic approaches: a systematic review and meta- analysis. Int J Urol. 2013;20:312–21.

    Article  PubMed  Google Scholar 

  11. Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1–15.

    Article  PubMed  Google Scholar 

  12. Al-Mamari SA, Quintens H, Mentine N, Burté C, Rouyer N, Jacob G, Amiel J. RALP: comparison of the oncological and functional outcomes of the intrafascial and the interfascial approaches. Prog Urol. 2015;25:54–61.

    Article  CAS  PubMed  Google Scholar 

  13. Schuessler WW, Schulam PG, Clayman RV, et al. Laparoscopic radical prostatectomy: initial short-term experience. Urology. 1997;50:854–7.

    Article  CAS  PubMed  Google Scholar 

  14. Guillonneau B, Vallencien G. Laparoscopic radical prostatectomy: initial experience and preliminary assessment after 65 operations. Prostate. 1999;39:71–5.

    Article  CAS  PubMed  Google Scholar 

  15. Barré C. Open radical retropubic prostatectomy. Eur Urol. 2007;52:71–80.

    Article  PubMed  Google Scholar 

  16. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–8.

    Article  CAS  PubMed  Google Scholar 

  17. Keegan KA, Cookson MS. Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep. 2011;12(3):203–8.

    Article  CAS  PubMed  Google Scholar 

  18. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50(5):1006–13.

    Article  PubMed  Google Scholar 

  19. New Classification of Physical Status. Anesthesiology. 1963; 24:111. http://www.asahq.org/search?q=asa%20physical%20status%20classification%20system

  20. Riou O, Regnault de la Mothe P, Azria D, Ailleres N, Dubois JB, Fenoglietto P. Simultaneous integrated boost plan comparison of volumetric- modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer. J Appl Clin Med Phys. 2013;14:4094.

    PubMed  Google Scholar 

  21. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24(33):5298–304.

    Article  PubMed  Google Scholar 

  22. Brousil P, Hussain M, Lynch M, Laing RW, Langley SE. Modified TURP for men with moderate LUTS prior to brachytherapy is safe and feasible. BJU Int. 2014. doi: 10.1111/bju.12798. [Epub ahead of print].

  23. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–99.

    Article  CAS  PubMed  Google Scholar 

  24. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  25. Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin M, et al. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer. 2010;116(4):837–42.

    Article  PubMed  Google Scholar 

  26. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer 2007 update. J Urol. 2007;177(6):2106–31.

    Article  PubMed  Google Scholar 

  27. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol. 2007;52:29–37.

    Article  PubMed  Google Scholar 

  28. Schiavina R, Manferrari F, Garofalo M, Bertaccini A, Vagnoni V, Guidi M, Borghesi M, Baccos A, Morselli-Labate AM, Concetti S, Martorana G. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer. BJU Int. 2011;108(8):1262–8.

    Article  CAS  PubMed  Google Scholar 

  29. Ploussard G, Briganti A, de la Taille A, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications—a systematic review of the literature. Eur Urol. 2014;65:7–16.

    Article  PubMed  Google Scholar 

  30. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short- term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–18.

    Article  CAS  PubMed  Google Scholar 

  31. Peneau M, Villers A, Molinie V, Theis D, Soulié M. Indications de la lymphadénectomie ilio- obturatrice dans le cancer de prostate cliniquement localisé. Prog Urol. 2004;14:287–94.

    PubMed  Google Scholar 

  32. Roach M. Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol. 2004;6 Suppl 8:S24–31.

    PubMed Central  PubMed  Google Scholar 

  33. Lee JY, Cho KS, Kwon JK, Jeh SU, Kang HW, Diaz RR, Ham WS, Koom WS, Keum KC, Choi YD. A competing risk analysis of cancer-specific mortality of initial yreatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer. Ann Surg Oncol. 2014;21(12):4026–33.

    Article  PubMed  Google Scholar 

  34. Furubayashi N, Nakamura M, Hishikawa K, et al. Radical prostatectomy as radical cure of prostate cancer in a high-risk group: a single-institution experience. Mol Clin Oncol. 2013;1(2):337–42.

    PubMed Central  PubMed  Google Scholar 

  35. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5- year results. J Urol. 2002;167:112–6.

    Article  PubMed  Google Scholar 

  36. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, et al. Long- term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791–4.

    Article  CAS  PubMed  Google Scholar 

  37. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three- month neoadjuvant hormonal therapy before radical prostatectomy: a 7- year follow- up of a randomized controlled trial. BJU Int. 2002;90:561–6.

    Article  CAS  PubMed  Google Scholar 

  38. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4- year follow- up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38:706–13.

    Article  CAS  PubMed  Google Scholar 

  39. Van Poppel H. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. Eur Urol 2001; 39:10–4. Prezioso D, Lotti T, Polito M, Montironi R. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 2004; 72:189–95.

    Google Scholar 

  40. Rebillard X, Soulié M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, et al. High- intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int. 2008;101:1205–13.

    Article  PubMed  Google Scholar 

  41. Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L,Cornu F, et al. Comité de Cancérologie de l’AFU. Recommandations en onco- urologie: cancer de la prostate. Prog Urol 2010; 20:S217–51.

    Google Scholar 

  42. Finley DS, Pouliot F, Miller DC, Belldegrun AS. Primary and salvage cryotherapy for prostate cancer. Urol Clin North Am. 2010;37:67–82.

    Article  PubMed  Google Scholar 

  43. Quero L, Wong-Hee-Kam S, Rivera S, Hennequin C. Association of radiotherapy and hormonotherapy in locally advanced prostate cancer. Bull Cancer. 2012;99 Suppl 1:S30–6.

    PubMed  Google Scholar 

  44. Bolla M, de Reijke TM, Van Tienhoven G et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360(24):2516–27.

    Google Scholar 

  45. Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572–8.

    Google Scholar 

  46. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate- specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.

    Article  PubMed  Google Scholar 

  47. Thompson Jr IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long- term follow up of a randomized clinical trial. J Urol. 2009;181:956–62.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf Jr JS, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190(2):441–9.

    Article  PubMed  Google Scholar 

  49. Kang YJ, Kim KH, Lee KS. Efficacy of bicalutamide 150-mg monotherapy compared with combined androgen blockade in patients with locally advanced prostate cancer. Korean J Urol. 2014;55(5):315–20.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists’ Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105(8):1074–81.

    Article  CAS  PubMed  Google Scholar 

  51. Mg O, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005–7.

    Article  Google Scholar 

  52. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node- positiveprostate cancer. J Clin Oncol. 2009;27:100–5.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park). 2009;23(7):626–30.

    Google Scholar 

  54. Hancock SL, Cox RS, Bagshaw MA. Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol. 1995;154(4):1412–7.

    Article  CAS  PubMed  Google Scholar 

  55. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol. 2006;176(4 Pt 1):1404–8.

    Article  PubMed  Google Scholar 

  56. Mn S, Aj S, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175–84.

    Article  Google Scholar 

  57. Soulié M, Beuzeboc P, Cornud F, Eschwege P, Gaschignard N, Grosclaude P, et al. Comité de Cancérologie de l’Association Française d’Urologie. Recommandations 2007 en onco- urologie. Cancer de la prostate. Prog Urol 2007;17:1157–230.

    Google Scholar 

  58. Roach 3rd M, Hanks G, Thames HJR, Schellhammer P, Shipley WU, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG- ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.

    Article  PubMed  Google Scholar 

  59. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology. 2002;59:740–6.

    Article  PubMed  Google Scholar 

  60. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006;64(4):1140–50.

    Article  PubMed  Google Scholar 

  61. Palma D, Tyldsley S, Blood P, Liu M, Morris J, Pickles T. Prostate cohort outcomes initiative: pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67:1425–9.

    Article  CAS  PubMed  Google Scholar 

  62. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10 year biochemical (PSA) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40.

    Article  CAS  PubMed  Google Scholar 

  63. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol. 2008;53(3):547–53.

    Article  CAS  PubMed  Google Scholar 

  64. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, et al. High- intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. 2009;104:1058–62.

    Article  CAS  PubMed  Google Scholar 

  65. Cytron S, Greene D, Witzsch U, Nylund P, Bjerklund Johansen TE. Cryoablation of the prostate: technical recommendations. Prostate Cancer Prostatic Dis. 2009;12(4):339–46.

    Article  CAS  PubMed  Google Scholar 

  66. De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000;85:281.

    Article  Google Scholar 

  67. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60(2 Suppl 1):3.

    Article  PubMed  Google Scholar 

  68. Salomon L, Bastide C, Beuzeboc P, et al. Les membres du CCAFU. Recommandations en onco-urologie 2013 du CCAFU: Cancer de la prostate. Prog Urol, 2013;23(Suppl 2): S69–101. p. 20.

    Google Scholar 

  69. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. The European Association of Urology. 2014. p. 133–4. Available from http://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf#.

  70. Flavio B, Valeria P. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int. 2014;2014:316272.

    Google Scholar 

  71. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25(22):3281–7.

    Article  PubMed  Google Scholar 

  72. Buskirk SJ, Pisansky TM, Schild SE, MacDonald OK, Wehle MJ, Kozelsky TF, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006;176:985–90.

    Article  PubMed  Google Scholar 

  73. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–41.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer. 2012;48(6):837–44.

    Article  PubMed  Google Scholar 

  75. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104–11.

    Article  PubMed  Google Scholar 

  76. Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st- century radiotherapy. Eur Urol. 2010;57:437–43.

    Article  PubMed  Google Scholar 

  77. Newling DW. Early versus late androgen deprivation therapy in metastatic disease. Urology. 2001;58(2 Suppl 1):50–5.

    Article  CAS  PubMed  Google Scholar 

  78. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008;101(9):1077–83.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149(3):607–9.

    CAS  PubMed  Google Scholar 

  80. Gauthier H, Bousquet G, Pouessel D, Culine S. Abiraterone acetate withdrawal syndrome: does it exist? Case Rep Oncol. 2012;5(2):385–7.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Phillips R. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome. Nat Rev Urol. 2014;11(7):366.

    Article  PubMed  Google Scholar 

  82. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem. 2004;91(1):3–12.

    Article  CAS  PubMed  Google Scholar 

  83. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006;24(Suppl):8528.

    Google Scholar 

  84. Fizazi K, Carducci M, Smith M, Damio R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration- resistant prostate cancer: a randomised, double- blind study. Lancet. 2011;377:813–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Anselmetti GC. Osteoplasty: percutaneous bone cement injection beyond the spine. Semin Intervent Radiol. 2010;27(2):199–208.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013;63(2):309–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341–51.

    Article  CAS  PubMed  Google Scholar 

  88. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190(2):429–38.

    Article  PubMed  Google Scholar 

  89. Basch E, Loblaw DA, Oliver TK et al. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2014;32(30):3436–48.

    Google Scholar 

  90. Merseburger AS, Scher HI, Bellmunt J, et al. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2014. doi:10.1111/bju.12898. [Epub ahead of print].

    PubMed Central  PubMed  Google Scholar 

  91. Ouzaid I, Ravery V. Sipuleucel-T: a prostate cancer vaccine: “instructions for use” for urologists. Prog Urol. 2011;21(9):595–8.

    Article  CAS  PubMed  Google Scholar 

  92. Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology. 2013;2(5):e24523.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari & Salim Said Al-Busaidy (Senior Consultant and HOD)

Authors
  1. Said Abdallah Al-Mamari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salim Said Al-Busaidy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Said Abdallah Al-Mamari .

Editor information

Editors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari

  2. Urology Department, The Royal Hospital, Muscat, Oman

    Salim Said Al-Busaidy

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Al-Mamari, S.A., Al-Busaidy, S.S. (2015). Treatment of the Prostate Cancer. In: Al-Mamari, S., Al-Busaidy, S. (eds) Urological Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-319-16301-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16301-7_4

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16300-0

  • Online ISBN: 978-3-319-16301-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation